Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Furmonertinib

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    ArriVent BioPharma Reports First Quarter 2024 Financial Results
    ArriVent BioPharma Reports First Quarter 2024 Financial Results

    08 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/08/2877780/0/en/ArriVent-BioPharma-Reports-First-Quarter-2024-Financial-Results.html

    GLOBENEWSWIRE
    08 May 2024
    Share Share
    InnoCare Announces of First Dosing of the Combination of ICP-189 & Furmonertinib
    InnoCare Announces of First Dosing of the Combination of ICP-189 & Furmonertinib

    28 Mar 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240328167713/en

    BUSINESSWIRE
    28 Mar 2024
    Share Share
    ArriVent Receives FDA Breakthrough Therapy Designation for Furmonertinib
    ArriVent Receives FDA Breakthrough Therapy Designation for Furmonertinib

    30 Oct 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/10/30/2768968/0/en/ArriVent-Receives-FDA-Breakthrough-Therapy-Designation-for-Furmonertinib-for-First-Line-Treatment-of-Advanced-or-Metastatic-Non-Small-Cell-Lung-Cancer-with-EGFR-Exon-20-Insertion-M.html

    GLOBENEWSWIRE
    30 Oct 2023
    Share Share
    InnoCare Announces Approval of Clinical Trial of SHP2 Inhibitor ICP-189
    InnoCare Announces Approval of Clinical Trial of SHP2 Inhibitor ICP-189

    13 Sep 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230913778402/en

    BUSINESSWIRE
    13 Sep 2023
    Share Share